Navigation Links
WellGen, Inc. Launches Te Ame(TM) Nutritional Supplements With Proven Health Benefits of Proprietary Black Tea Extract
Date:5/13/2009

tea extract were conducted in WellGen's laboratories at the Commercialization Center for Innovative Technologies in North Brunswick, New Jersey, in the Human Performance Laboratory at Rutgers University, and at university and private research centers across the country.

Dr. Nancy Rawson, Chief Scientific Officer of WellGen, said, "Our research programs are teaching us a great deal about how foods influence health at the very basic level of our genes. With that expertise, WellGen's talented and dedicated scientists have worked hard to discover the fundamental health benefits that can be derived from compounds occurring naturally in black tea. Although you can get black tea anywhere, this proprietary ingredient has been demonstrated to be effective in clinical studies.

"As scientists, seeing these discoveries translated into Te Ame products with real health benefits is incredibly rewarding and exciting," she said.

Te Ame(TM) products will be sold online at Te-Ame.com. The web site provides additional product description and more information about Te Ame. It also invites consumers to be part of the Te Ame community by posting their own comments, reading blogs about Te Ame written by the company's scientific and product development professionals, and through other social networking features.

Te Ame is the only brand of nutritional supplements that provides such a range of health and wellness benefits from black tea extract. Equally important, the raw materials in every batch are rigorously tested to meet stringent criteria for both chemical and bioactivity standards. The brand Te Ame(TM) is targeted to adults, and especially to women, who face many different wellness challenges. Te Ame(TM) Joint Care contains WellGen(R) theaflavin-enriched black tea extract which works in less than a week and also contains glucosamine. Clinical tests demonstrated that Te Ame(TM) Active Body soothes m
'/>"/>

SOURCE WellGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc.
2. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
3. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
4. Amnis Launches New ImageStreamX Imaging Flow Cytometer
5. Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University
6. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
7. Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tephas Proprietary Biomaterial
8. Elsevier Launches Ten New eBook Specialty Collections on MD Consult
9. Histogen Aesthetics Launches ReGenica Rejuvenation System
10. AMG Launches EVOS fl, an 'Evolutionary' Fluorescence Microscope Based on Innovative EVOS Platform
11. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Martek Biosciences Corporation (Nasdaq: MATK ) ... and fiscal year ended October 31, 2009. Revenues for ... $90.4 million in the fourth quarter of fiscal 2008. ... share, for the fourth quarter of fiscal 2009, a ... diluted share, in last year,s fourth quarter. The ...
(Date:12/16/2009)... microgears in suspended solution by swimming , ... ... Scientists at the U.S. Department of Energy’s (DOE) Argonne National ... bacteria can turn microgears when suspended in a solution, providing ... , , ,“The gears are a million times more massive ...
(Date:12/16/2009)... -- Decision Resources, one of the world,s leading ... issues, finds that, according to responses from surveyed ... (both interleukin inhibitors) will capture 22 percent of ... market for moderate to severe psoriasis. Among these ... nearly three times as much patient share as ...
(Date:12/16/2009)... to Special Protocol Assessment with the Food ... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... a global biopharmaceutical company focused on oncology ... by its partner Keryx Biopharmaceuticals Inc. ("Keryx") ... clinical trial for perifosine (KRX-0401), the Company,s ...
Breaking Biology Technology:Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5
... Specimen Management Provide FocusMEMPHIS, Tenn., April 22 ... Accelerated Community Oncology Research Network, Inc. (ACORN) and ... human tissue samples for scientific research. In ... storage in conjunction with clinical trial operations and ...
... Calif., April 22 Metabolex, Inc., a biopharmaceutical company ... therapeutics for the treatment of diabetes and related metabolic ... to its Board of Directors. Mr. von Emster currently ... November 2000 to March 2009, Mr. von Emster was ...
... Inc., a leading provider of software and databases for ... that the University of Cardiff has become a certified ... access to GeneGo,s MetaCore, training and advanced support. ... with GeneGo to provide a pathway analysis environment for ...
Other Biology Technology:World BioBank(TM) Launch Benefits Advanced Medical Research 2World BioBank(TM) Launch Benefits Advanced Medical Research 3Metabolex Announces Election of Kurt von Emster to Board of Directors 2Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:12/16/2009)... that short-term, seasonal exposure to pesticides in rivers ... of wild salmon populations. In addition to the ... that exposure to commonly used pesticides may further ... , "Major efforts are currently underway to ... recover depressed populations," says David Baldwin of the ...
(Date:12/16/2009)... a global provider of business process outsourcing (BPO) services, ... Awards Top 100 IT project of 2009 for its ... for iQor. ,, "We are honored to be recognized ... president and CEO of iQor. "TeQ21 is completely transforming ... faster, smarter and with the added security biometrics provides. ...
(Date:12/16/2009)... N.J., Dec. 3 BIO-key International, ... in wireless public safety and finger-based biometric ... its shareholders at a Special Shareholder Meeting ... company,s Law Enforcement Division to Interact911 Mobile ... were cast in favor and 1.2% were ...
Breaking Biology News(10 mins):Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Concussion experts 3A For kids no sports no schoolwork no text messages 48183 1Concussion experts 3A For kids no sports no schoolwork no text messages 48183 2New research program BioInterfaces launched 8742 1New research program BioInterfaces launched 8742 2Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 1Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 2
... salt cedar eatersthan beetles from Greece. At least ... Uzbekistan salt cedar beetles being released by the ... those released onthe salt cedar stands near Lake ... said Vanessa Carney, Experiment Station entomologyresearch associate. , ...
... may have broader implications for understanding kidney disorders, ... have identified a second gene that gives rise ... affects multiple organs. The Children's Hospital team previously ... , The researchers found that mutations in the ...
... arterial blockages related to diabetes, smoking, obesity and ... rate. Yet physicians may be too quick to ... preventable, according to the International Diabetes Foundation. , ... are more dangerous and more expensive than revascularization, ...
Other Biology News:Better beetle sought for salt cedar control 2Better beetle sought for salt cedar control 3Gene discovery may shed light on kidney disease 2Epidemic of unneeded amputations 2
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
... (Aph-1aL,S Loop 92-115), O2F1 Affinity Purified ... multiprotein complex consisting of presenilin, nicastrin, ... are necessary for full proteolytic activity. ... of a number of integral membrane ...
TGase3 (S-20)...
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
Biology Products: